T20 vs T80.82XS
T20 (Burn and corrosion of head, face, and neck) compared with T80.82XS (Complication of immune effector cellular therapy, sequela), from the official CMS tabular data. Both may be reported when both conditions are documented (Excludes2).
Can these codes be reported together?
Yes, when both are documented. T80.82XS carries an Excludes2 note covering T20: “burns and corrosions from local applications and irradiation (T20-T32)”
Excludes2 marks distinct conditions — both may be reported when both are documented.
Side by side
| T20Burn and corrosion of head, face, and neck | T80.82XSComplication of immune effector cellular therapy, sequela | |
|---|---|---|
| Billing status | Non-billable header Report instead: T20.00XA, T20.00XD, T20.00XS, T20.011A, T20.011D | Billable |
| Classification | S00-T88 — Injury, Poisoning and Certain Other Consequences of External Causes (S00-T88) | S00-T88 — Injury, Poisoning and Certain Other Consequences of External Causes (S00-T88) |
| Definition | Burn and corrosion of head, face, and neck is a non-billable ICD-10-CM category code (T20). | Complication of immune effector cellular therapy, sequela is a billable ICD-10-CM diagnosis code (T80.82S). |
| 7th character | The appropriate 7th character is to be added to each code from category T20 | The appropriate 7th character is to be added to each code from category T80 |
| Includes | burns and corrosions of first degree [erythema] burns and corrosions of second degree [blisters][epidermal loss] burns and corrosions of third degree [deep necrosis of underlying tissue] [full- thickness skin loss] | complications following perfusion Complication of chimeric antigen receptor (CAR-T) cell therapy Complication of IEC therapy |
| Use additional code | code from category T31 or T32 to identify extent of body surface involved | code to identify the specific complication, such as: cytokine release syndrome (D89.83-) immune effector cell-associated neurotoxicity syndrome (G92.0-) |
Derived from the official CMS ICD-10-CM tabular data (FY2026). Not billing advice; verify sequencing rules for the encounter. All data sources